 |
TSO3: an additional sale wraps up the Referral Site programSeptember 27, 2007Québec City, September 27, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces the sale of a 125L Ozone Sterilizer to the last remaining hospital participating in the Referral Site Program. This sale concludes the program.A Canadian leader in trauma care for more than 35 years, this hospital has served as a tertiary trauma center, offering highly specialized care within its province, since 1992. Owing to its expertise both in microbiology and infection prevention, this center is also considered a reference in sterilization. “Our primary goal was to cut down on the use of Ethylene Oxide for low temperature sterilization in compliance with the Canadian regulation1 concerning the reduction of emission of this toxic gas”, stated the person in charge of central sterilization at the hospital at the time of trial of the 125L Ozone Sterilizer. “Our personnel have been pleased with its simplicity of operation. Using ozone sterilization has lead to substantial savings, but also to a more effective material distribution, since this method is faster.” “Ozone sterilization answers many needs in sterilization, such as reducing the use of pollutants and toxic gases like Ethylene Oxide. This sale is a concrete example of that,” stated Jocelyn Vézina, CEO for TSO3 Inc. “We are pleased to see such a proactive and renowned hospital become a satisfied user and a buyer of ozone sterilization.” As a reminder, Environment Canada has asked hospitals to reduce their Ethylene Oxide releases in the environment by 99%. 1 Guidelines for the Reduction of Ethylene Oxide Releases from Sterilization Applications About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 65 employees, about half of whom work in the sales and marketing team. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
